Elsevier

IJID Regions

Volume 2, March 2022, Pages 198-203
IJID Regions

Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection

https://doi.org/10.1016/j.ijregi.2022.01.013Get rights and content
Under a Creative Commons license
open access

Highlights

  • 30% of the Bangladeshi population were found to be seropositive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin G antibodies.

  • The highest seroprevalence rate (64%) was found in slum areas in Bangladesh.

  • Thirty-eight percent and 29% of participants from urban and rural areas were SARS-CoV-2 seropositive.

  • The highest seroprevalence rate for coronavirus disease 2019 was observed in August 2020.

ABSTRACT

Design

A cross-sectional study was conducted amongst household members in 32 districts of Bangladesh to build knowledge about disease epidemiology and seroepidemiology of coronavirus disease 2019 (COVID-19).

Objective

Antibody responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were assessed in people between April and October 2020.

Results

The national seroprevalence rates of immunoglobulin G (IgG) and IgM were estimated to be 30.4% and 39.7%, respectively. In Dhaka, the seroprevalence of IgG was 35.4% in non-slum areas and 63.5% in slum areas. In areas outside of Dhaka, the seroprevalence of IgG was 37.5% in urban areas and 28.7% in rural areas. Between April and October 2020, the highest seroprevalence rate (57% for IgG and 64% for IgM) was observed in August. IgM antibody was more prevalent in younger participants, while older participants had more frequent IgG seropositivity. Follow-up specimens from patients with COVID-19 and their household members suggested that both IgG and IgM seropositivity increased significantly at day 14 and day 28 compared with day 1 after enrolment. Conclusions: SARS-CoV-2 had spread extensively in Bangladesh by October 2020. This highlights the importance of monitoring seroprevalence data, particularly with the emergence of new SARS-CoV-2 variants over time.

Keywords

Seroprevalence
Antibodies
Bangladesh
COVID-19

Cited by (0)

Joint first authors.

Joint senior authors.